Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 07, 2022 07:00 ET | Source: Algernon Pharmaceuticals

Algernon Pharmaceuticals Provides Update on Its Phase 1 DMT Stroke Study

VANCOUVER, British Columbia, July 07, 2022 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a clinical stage Canadian...
January 17, 2020 06:00 ET | Source: Algernon Pharmaceuticals

Algernon Pharmaceuticals Appoints Novotech as CRO for First Phase 2 Trial and Announces Novotech’s $220K Equity Investment

VANCOUVER, British Columbia, Jan. 17, 2020 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”), a clinical stage pharmaceutical...
December 30, 2019 06:00 ET | Source: Algernon Pharmaceuticals

Algernon Pharmaceuticals Announces OTC Trading Symbol Change to AGNPF

VANCOUVER, British Columbia, Dec. 30, 2019 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmaceutical...
July 03, 2019 07:00 ET | Source: Algernon Pharmaceuticals

Algernon Pharmaceuticals’ NP-120 Reduced Fibrosis in an Idiopathic Pulmonary Fibrosis Study by 56% Outperforming USFDA Approved Treatments Nintedanib and Pirfenidone

VANCOUVER, British Columbia, July 03, 2019 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCB: BTHCF) (the “Company” or “Algernon”), a clinical stage pharmaceutical...
February 19, 2019 07:00 ET | Source: Algernon Pharmaceuticals

Algernon Pharmaceuticals Begins Trading on The CSE Under The Symbol AGN

VANCOUVER, British Columbia, Feb. 19, 2019 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) a clinical stage pharmaceutical development company is pleased to announce...